Cargando…

Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid

S. aureus is a pathogen that frequently causes severe morbidity and phage therapy is being discussed as an alternative to antibiotics for the treatment of S. aureus infections. In this in vitro and animal study, we demonstrated that the activity of anti-staphylococcal phages is severely impaired in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mutti, Michele, Moreno, David Sáez, Restrepo-Córdoba, Marcela, Visram, Zehra, Resch, Grégory, Corsini, Lorenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598271/
https://www.ncbi.nlm.nih.gov/pubmed/37875544
http://dx.doi.org/10.1038/s41598-023-45405-8
_version_ 1785125518462418944
author Mutti, Michele
Moreno, David Sáez
Restrepo-Córdoba, Marcela
Visram, Zehra
Resch, Grégory
Corsini, Lorenzo
author_facet Mutti, Michele
Moreno, David Sáez
Restrepo-Córdoba, Marcela
Visram, Zehra
Resch, Grégory
Corsini, Lorenzo
author_sort Mutti, Michele
collection PubMed
description S. aureus is a pathogen that frequently causes severe morbidity and phage therapy is being discussed as an alternative to antibiotics for the treatment of S. aureus infections. In this in vitro and animal study, we demonstrated that the activity of anti-staphylococcal phages is severely impaired in 0.5% plasma or synovial fluid. Despite phage replication in these matrices, lysis of the bacteria was slower than phage propagation, and no reduction of the bacterial population was observed. The inhibition of the phages associated with a reduction in phage adsorption, quantified to 99% at 10% plasma. S. aureus is known to bind multiple coagulation factors, resulting in the formation of aggregates and blood clots that might protect the bacterium from the phages. Here, we show that purified fibrinogen at a sub-physiological concentration of 0.4 mg/ml is sufficient to impair phage activity. In contrast, dissolution of the clots by tissue plasminogen activator (tPA) partially restored phage activity. Consistent with these in vitro findings, phage treatment did not reduce bacterial burdens in a neutropenic mouse S. aureus thigh infection model. In summary, phage treatment of S. aureus infections inside the body may be fundamentally challenging, and more investigation is needed prior to proceeding to in-human trials.
format Online
Article
Text
id pubmed-10598271
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-105982712023-10-26 Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid Mutti, Michele Moreno, David Sáez Restrepo-Córdoba, Marcela Visram, Zehra Resch, Grégory Corsini, Lorenzo Sci Rep Article S. aureus is a pathogen that frequently causes severe morbidity and phage therapy is being discussed as an alternative to antibiotics for the treatment of S. aureus infections. In this in vitro and animal study, we demonstrated that the activity of anti-staphylococcal phages is severely impaired in 0.5% plasma or synovial fluid. Despite phage replication in these matrices, lysis of the bacteria was slower than phage propagation, and no reduction of the bacterial population was observed. The inhibition of the phages associated with a reduction in phage adsorption, quantified to 99% at 10% plasma. S. aureus is known to bind multiple coagulation factors, resulting in the formation of aggregates and blood clots that might protect the bacterium from the phages. Here, we show that purified fibrinogen at a sub-physiological concentration of 0.4 mg/ml is sufficient to impair phage activity. In contrast, dissolution of the clots by tissue plasminogen activator (tPA) partially restored phage activity. Consistent with these in vitro findings, phage treatment did not reduce bacterial burdens in a neutropenic mouse S. aureus thigh infection model. In summary, phage treatment of S. aureus infections inside the body may be fundamentally challenging, and more investigation is needed prior to proceeding to in-human trials. Nature Publishing Group UK 2023-10-24 /pmc/articles/PMC10598271/ /pubmed/37875544 http://dx.doi.org/10.1038/s41598-023-45405-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mutti, Michele
Moreno, David Sáez
Restrepo-Córdoba, Marcela
Visram, Zehra
Resch, Grégory
Corsini, Lorenzo
Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid
title Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid
title_full Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid
title_fullStr Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid
title_full_unstemmed Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid
title_short Phage activity against Staphylococcus aureus is impaired in plasma and synovial fluid
title_sort phage activity against staphylococcus aureus is impaired in plasma and synovial fluid
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598271/
https://www.ncbi.nlm.nih.gov/pubmed/37875544
http://dx.doi.org/10.1038/s41598-023-45405-8
work_keys_str_mv AT muttimichele phageactivityagainststaphylococcusaureusisimpairedinplasmaandsynovialfluid
AT morenodavidsaez phageactivityagainststaphylococcusaureusisimpairedinplasmaandsynovialfluid
AT restrepocordobamarcela phageactivityagainststaphylococcusaureusisimpairedinplasmaandsynovialfluid
AT visramzehra phageactivityagainststaphylococcusaureusisimpairedinplasmaandsynovialfluid
AT reschgregory phageactivityagainststaphylococcusaureusisimpairedinplasmaandsynovialfluid
AT corsinilorenzo phageactivityagainststaphylococcusaureusisimpairedinplasmaandsynovialfluid